The Prostate Cancer Therapeutics Market Report presents a thorough analysis of the market and brings up the growth opportunities by different segments such as therapy type, regions.
What Are the Driving Factors for Prostate Cancer Therapeutics Market?
- Increasing number of patients in emerging economies, developed nations
- Growing usage of hormone-refractory prostate cancer drugs
- Approval of new drugs such as Xofigo of Bayer, enzalutimide, and inclusion of new curative methods
|By Therapy Type||Biologic Therapy, Chemotherapy, Hormone Therapy and Others|
|By Regions||North America, Asia-Pacific, Europe, Middle East & Africa and Latin America|
|The U.S.||Pfizer, Inc., Johnson & Johnson, Amgen, Inc.|
Why Buy this Prostate Cancer Therapeutics Market Report?
- The report provides in-depth analysis of market determinant factors.
- It analyzes market dynamics for each segment (such as Therapy Type, Regions).
- This report provides 8 years forecast by analyzing push and pull factors affecting the dynamics of the market.
- It provides application level cross-sectional analysis for each product type.
- It provides regional level pricing trend analysis.
- This market report acts as business decision support system by analyzing key trends in each market segment.
- It provides insights regarding business strategies of leading market players.
Prostate Cancer Therapeutics Market - Introduction
The global prostate cancer therapeutics market is expected to grow at a fast pace during the forecast period 2017 to 2025. In the prostate cancer therapeutics market report, the market is segmented based on therapy type and region. The prostate is a gland in the male reproductive system and development of cancer in that gland is termed as prostate cancer. The exact causes of prostate cancer are unknown but are generally linked to hereditary causes or to unhealthy diet and lifestyle. Studies suggest that high consumption of red meat and processed meat increases the chances of prostate cancer, while family history of prostate cancer also increases the risk by manifolds. Prostate cancer is also often linked to exposure to harmful chemicals and pathogens among others. Prostate cancer has relatively low mortality rate and the combination of prostate cancer therapeutics has been found to increase the survival rate to a large extent. While prostate cancer is most prevalent in developed nations, the growing patient pool in emerging economies has been primarily driving the prostate cancer therapeutics market revenue and volume.
|Base Year of Estimation||2016|
|Value Estimation Year||2017|
|Forecast Period||2017 - 2025|
|Market Segmentations||By Therapy Type, Regions|
|Regional Scope||North America, Asia-Pacific, Europe, Middle East & Africa and Latin America|
|Report Coverage||Market Dynamics, Segmentation Overview and Competitive Landscape of the market|
Prostate Cancer Therapeutics Market Dynamics
Prostate cancer therapeutics market growth trends are primarily due to the rising patient pool globally. Studies reveal that the number of prostate cancer patients has been growing at a high pace in emerging economies, apart from the fast growth rates in developed nations. As per the World Health Organization (WHO), prostate cancer is the fourth most prevalent form of cancer and approximately 1.1 million males were diagnosed with the disease in 2012. A significant rise in prostate cancer cases was noticed in countries such as Denmark, Singapore, Slovakia Colombia and Costa Rica among other countries. Such growing number of the patient population has led to increasing demand for the different types of prostate cancer therapeutics, thus positively impacting the growth of the prostate cancer therapeutics market size.
The growing usage of hormone-refractory prostate cancer drugs, coupled with the approval of several new drugs and therapies has also been driving the growth of the prostate cancer therapeutics market. Hormone-refractory prostate cancer drugs have been found to have relatively lesser adverse effects, thus having higher acceptance in patients, which in turn has been boosting the growth of prostate cancer therapeutics market.
Lack of proper diagnosis methods and relatively high cost of treatment are some of the factors which have been restraining the growth rate of prostate cancer therapeutics market. Since prostate cancer is mostly asymptomatic, low diagnosis rates decrease the chances of the patients receiving the drugs at the optimum time, thus restraining the growth. However, the approval of several new prostate cancer drugs, such as Xofigo of Bayer and enzalutimide among others, is expected to negate such restraints for the prostate cancer therapeutics market and is also expected to offer good growth opportunities.
The global prostate cancer therapeutics market is segmented, based on therapy type, into biologic therapy, chemotherapy, hormone therapy and others. Chemotherapy has been sub-segmented into systemic chemotherapy and regional chemotherapy. Hormone therapy has again been segmented into luteinizing hormone-releasing hormone (LHRH) analogues, LHRH antagonists, and others. Hormone therapy is the most preferred form of therapy in prostate cancer patients and hence was the leading segment of the prostate cancer therapeutics segment in 2016, by revenue.
By geography, the market has been segmented into Europe, North America, Middle East & Africa (MEA), Asia Pacific and Latin America. In terms of revenue, North America accounted for the largest market share of the prostate cancer therapeutics market, followed by Europe.
Major companies operating in the prostate cancer therapeutics market are Pfizer, Inc. (The U.S.), AstraZeneca Plc (England), Bayer AG. (Germany), Johnson & Johnson (The U.S.), Amgen, Inc. (The U.S.), and Sanofi S.A. (France) among others.
|Related Upcoming Report Titles|
|Get Free Samples for Market Research Reports. The privacy and security of your shared information are very important to us. Our website is secure and your personal details are safe.|